QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$12.36
-0.33 (-2.60%)
(As of 02/3/2023 10:46 AM ET)
Add
Compare
Today's Range
$12.24
$12.51
50-Day Range
$8.92
$12.69
52-Week Range
$6.00
$23.78
Volume
82,064 shs
Average Volume
761,107 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
53.1% Upside
$18.92 Price Target
Short Interest
Healthy
3.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of NeoGenomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

176th out of 1,029 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Why Shares of NeoGenomics Jumped 53.9% This Week
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
NeoGenomics Reports Third Quarter 2022 Results
NeoGenomics, Inc. (NASDAQ: NEO)
Here’s How Artisan Partners Views NeoGenomics (NEO)
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.92
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+53.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-8,350,000.00
Pretax Margin
-35.84%

Debt

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.19 per share
Book Value
$9.00 per share

Miscellaneous

Free Float
125,040,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Chris Smith
    Chief Executive Officer
  • Jeffrey Scott Sherman
    Chief Financial Officer
  • Steven A. Ross
    Chief Information Officer & Vice President
  • David Sholehvar
    President-Clinical Services
  • John Mooney
    Chief Technology Officer













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

12 analysts have issued twelve-month target prices for NeoGenomics' shares. Their NEO share price forecasts range from $12.00 to $30.00. On average, they predict the company's stock price to reach $18.92 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 at the beginning of 2023. Since then, NEO shares have increased by 37.3% and is now trading at $12.69.
View the best growth stocks for 2023 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, November, 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The medical research company earned $128.78 million during the quarter, compared to analysts' expectations of $122.55 million. NeoGenomics had a negative net margin of 32.88% and a negative trailing twelve-month return on equity of 9.46%.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.21%), Perkins Capital Management Inc. (0.16%), Oak Family Advisors LLC (0.08%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%) and Nisa Investment Advisors LLC (0.04%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $12.69.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.60 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,000 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 2/3/2023 by MarketBeat.com Staff